{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:53:50Z","timestamp":1787738030984,"version":"build-2784847793"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Drug-induced pancreatitis is a rare disease but frequently reported, owing to the vast number of medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To summarize potential drugs causing pancreatitis and to speculate on underlying mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We extracted more than 60,000 reports of pancreatitis submitted to the U.S. Food and Drug Administration Adverse Event Reporting System (January 2004 to March 2023). Data on patient age, sex, weight, time to onset, and outcome (death et al.) were collected. Disproportionality analysis was used in data mining to identify associations between drugs and pancreatitis events. Seven databases, commonly used for network pharmacology analysis, were searched to identify potential targets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 867 drugs with 3 or more reports, 101 drugs met all criteria using disproportionality analysis and indicated a potential risk of pancreatitis. The risk of 40 drugs had not been previously noted in \u201cUpToDate\u201d database. Patients taking the drugs had a similar sex distribution, were mostly 45\u201364\u00a0years old, and were heavier (median, 88\u00a0kg; P &amp;lt; 0.0001). The median time to onset was 199 days (interquartile range, 27\u2013731.5). Ponatinib (16.48%), tigecycline (14.12%) and valproic acid (13.41%) had higher fatality rates. Potential targets related to pancreatitis were identified in 50 of the 101 drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Clinicians providing the 101 drugs for treatment should stay vigilant to detect pancreatitis early.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1564127","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:28:57Z","timestamp":1744781337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology"],"prefix":"10.3389","volume":"16","author":[{"given":"Hao","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnut.2017.00001","article-title":"Sphincter of Oddi function and risk factors for dysfunction","volume":"4","author":"Afghani","year":"2017","journal-title":"Front. Nutr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2165\/00002018-200831100-00002","article-title":"Drug-induced pancreatitis: incidence, management and prevention","volume":"31","author":"Balani","year":"2008","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.waojou.2021.100594","article-title":"Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: a real-world analysis of the Food and drug administration (fda) adverse event reporting system (faers)","volume":"14","author":"Bian","year":"2021","journal-title":"World Allergy Organ J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","article-title":"Comparison of statistical signal detection methods within and across spontaneous reporting databases","volume":"38","author":"Candore","year":"2015","journal-title":"Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"17562848211001725","DOI":"10.1177\/17562848211001725","article-title":"Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post us label change","volume":"14","author":"Cash","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1053\/j.gastro.2015.01.033","article-title":"Nfatc1 links egfr signaling to induction of Sox9 transcription and acinar-ductal transdifferentiation in the pancreas","volume":"148","author":"Chen","year":"2015","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"f3680","DOI":"10.1136\/bmj.f3680","article-title":"Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?","volume":"346","author":"Cohen","year":"2013","journal-title":"Bmj"},{"key":"B9","doi-asserted-by":"publisher","first-page":"107981","DOI":"10.1016\/j.diabres.2019.107981","article-title":"Pancreatitis and pancreatic cancer in patientes treated with dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials","volume":"159","author":"Dicembrini","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aaw3145","article-title":"The glycan Ca19-9 promotes pancreatitis and pancreatic cancer in mice","volume":"364","author":"Engle","year":"2019","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1007\/s10620-019-05928-5","article-title":"Identification of acute pancreatitis-related genes and pathways by integrated bioinformatics analysis","volume":"65","author":"Fan","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jcpt.12456","article-title":"Tocilizumab-induced pancreatitis: case report and review of data from the fda adverse event reporting system","volume":"41","author":"Flaig","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/pds.5313","article-title":"An investigation on the association between sodium glucose Co-transporter 2 inhibitors use and acute pancreatitis: a vigibase study","volume":"30","author":"Frent","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cgh.2017.08.006","article-title":"Risk of pancreatitis following treatment of irritable bowel syndrome with eluxadoline","volume":"16","author":"Gawron","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.3748\/wjg.v30.i41.4417","article-title":"Trypsin in pancreatitis: the culprit, a mediator, or epiphenomenon?","volume":"30","author":"Gukovskaya","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"f3750","DOI":"10.1136\/bmj.f3750","article-title":"Incretins and risk of neoplasia","volume":"346","author":"Halfdanarson","year":"2013","journal-title":"Bmj"},{"key":"B17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/apt.14504","article-title":"Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder","volume":"47","author":"Harinstein","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1592\/phco.24.13.1122.38098","article-title":"Application of an empiric bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics","volume":"24","author":"Hauben","year":"2004","journal-title":"Pharmacotherapy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4291\/wjgp.v5.i4.405","article-title":"Contemporary review of drug-induced pancreatitis: a different perspective","volume":"5","author":"Hung","year":"2014","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"18818","DOI":"10.1038\/s41598-021-98325-w","article-title":"Assessment of pancreatitis associated with tocilizumab use using the United States Food and drug administration adverse event reporting system database","volume":"11","author":"Kamath","year":"2021","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/MOG.0000000000000386","article-title":"Obesity and pancreatitis","volume":"33","author":"Khatua","year":"2017","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1046\/j.1365-2036.2003.01485.x","article-title":"Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis","volume":"17","author":"Lancashire","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0140-6736(14)60649-8","article-title":"Acute pancreatitis","volume":"386","author":"Lankisch","year":"2015","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ajg.2012.131","article-title":"Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis","volume":"107","author":"Lovell","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40780-019-0134-6","article-title":"Analysis of the association of administration of various glucocorticoids with development of acute pancreatitis using us Food and drug administration adverse event reporting system (faers)","volume":"5","author":"Nango","year":"2019","journal-title":"J. Pharm. Health Care Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12887-019-1571-y","article-title":"Evaluation of long-term effectiveness of the use of carglumic acid in patients with propionic acidemia (Pa) or methylmalonic acidemia (mma): study protocol for a randomized controlled trial","volume":"19","author":"Nashabat","year":"2019","journal-title":"BMC Pediatr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11894-012-0245-9","article-title":"Drug-induced pancreatitis","volume":"14","author":"Nitsche","year":"2012","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bpg.2010.02.002","article-title":"Drug induced pancreatitis","volume":"24","author":"Nitsche","year":"2010","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"G1015","DOI":"10.1152\/ajpgi.00349.2015","article-title":"Src kinases play a novel dual role in acute pancreatitis affecting severity but No role in stimulated enzyme secretion","volume":"310","author":"Nuche-Berenguer","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ncp.10379","article-title":"Chronic pancreatitis and nutrition therapy","volume":"34","author":"O'brien","year":"2019","journal-title":"Nutr. Clin. Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018","volume":"156","author":"Peery","year":"2019","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41598-017-19055-6","article-title":"Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis","volume":"8","author":"Pinto","year":"2018","journal-title":"Sci. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/14740338.2021.1933942","article-title":"Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data","volume":"20","author":"Qin","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1147572","DOI":"10.3389\/fphys.2023.1147572","article-title":"Cofilin activation in pancreatic acinar cells plays a pivotal convergent role for mediating cck-stimulated enzyme secretion and growth","volume":"14","author":"Ramos-Alvarez","year":"2023","journal-title":"Front. Physiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/MPA.0000000000001428","article-title":"Drug-induced acute pancreatitis in adults: an update","volume":"48","author":"Simons-Linares","year":"2019","journal-title":"Pancreas"},{"key":"B36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"Jama"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8298","DOI":"10.7150\/thno.46934","article-title":"Atf6 aggravates acinar cell apoptosis and injury by regulating P53\/aifm2 transcription in severe acute pancreatitis","volume":"10","author":"Tan","year":"2020","journal-title":"Theranostics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.14309\/ajg.0000000000002645","article-title":"American College of gastroenterology guidelines: management of acute pancreatitis","volume":"119","author":"Tenner","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1080\/10428194.2017.1397667","article-title":"Blinatumomab and pancreatitis: an analysis of faers, eudravigilance, and a large urban U.S. Patient population data","volume":"59","author":"Vakharia","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B41","doi-asserted-by":"publisher","first-page":"958","DOI":"10.2174\/1389200220666191122104955","article-title":"A retrospective look at anti-egfr agents in pancreatic cancer therapy","volume":"20","author":"Verma","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s10620-010-1277-3","article-title":"Incidence, severity, and etiology of drug-induced acute pancreatitis","volume":"55","author":"Vinklerov\u00e1","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2469273","article-title":"Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology","author":"Xie","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"599065","DOI":"10.3389\/fcell.2021.599065","article-title":"Cofilin: a promising protein implicated in cancer metastasis and apoptosis","volume":"9","author":"Xu","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3892\/etm.2022.11219","article-title":"Gelsolin impairs barrier function in pancreatic ductal epithelial cells by actin filament depolymerization in hypertriglyceridemia-induced pancreatitis in vitro","volume":"23","author":"Yang","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.eprac.2021.12.007","article-title":"Comparison of new glucose-lowering drugs on the risk of pancreatitis in type 2 diabetes: a network meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Endocr. Pract."},{"key":"B48","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41419-019-1919-0","article-title":"Atf6 regulates the development of chronic pancreatitis by inducing P53-mediated apoptosis","volume":"10","author":"Zhou","year":"2019","journal-title":"Cell. Death Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1564127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:28:58Z","timestamp":1744781338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1564127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":48,"alternative-id":["10.3389\/fphar.2025.1564127"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1564127","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1564127"}}